Vaccinated children: A powerful protection for older adults

July 10, 2013, Vanderbilt University Medical Center

Children who receive a vaccine to prevent blood and ear infections, appear to be reducing the spread of pneumonia to the rest of the population, especially their grandparents and other older adults. Results of a new Vanderbilt study, funded by the Centers for Disease Control and Prevention (CDC), and published in the July 11 issue of the New England Journal of Medicine show infant vaccination against pneumococcal bacteria since 2000 has reduced pneumonia hospitalization by more than 10 percent across the board, with the most significant reductions at the extreme ends of the age spectrum.

"Pneumonia is a leading cause of hospitalization in the United States. The protective effect we saw in older adults, who do not receive the but benefit from vaccination of infants, is quite remarkable. It is one of the most dramatic examples of indirect protection or herd immunity we have seen in recent years," said the study's first author, Marie Griffin, M.D., MPH, professor of Preventive Medicine and Medicine.

James Powers, M.D., associate professor of Medicine in Geriatrics, said the study suggests this herd immunity is an even more effective prevention for elders than the vaccine currently recommended to prevent pneumonia in older adults.

"The reduction in pneumonia hospitalizations among older adults appears to be related to long-term effects following introduction of PCV7 immunization for . We have not seen a similar response to the pneumovax 23 vaccine (recommended for older adults) introduced in 1983," Powers said.

Griffin, along with co-author Carlos Grijalva, M.D., MPH, assistant professor of Preventive Medicine, and their colleagues, examined a large national database for hospitalization from pneumonia from 1997 through 2009. The result is a long-term snapshot of how pneumococcal (PCV7 or Prevnar) has impacted pneumonia rates since it was added to the childhood vaccine list in 2000.

Results show children under age 2 experienced a 40 percent reduction in pneumonia hospitalizations. Reduction in hospitalizations of older children and adults—who did not receive the vaccine—while less dramatic, was still impressive. But researchers said what began as a slow decline in 2000 in the rate of pneumonia hospitalizations for adults over the age of 65, appeared to accelerate over the last decade. By 2009, more than half the nationwide decline in pneumonia hospitalizations could be attributed to older adults, with some 70,000 fewer annual hospitalizations for those age 85 and older.

"Humans are the only reservoir for the pneumococcus. This group of bacteria can live in the nose and throat of healthy people, especially children. From young children, these bacteria may be transmitted to older age groups. Over time, the vaccine is causing a change in types of pneumococcus carried and transmitted nationwide. We are very fortunate to witness this in our time. These huge indirect effects on the adult population don't happen very often," said Grijalva.

PCV7 was developed to protect children against seven types of that cause potentially deadly and debilitating blood and spinal infections. The bacteria are also well-known as a leading cause of lung and ear infections in young children. Early studies by the same Vanderbilt investigators showed a 30 percent reduction in childhood pneumonias in the first years after the vaccine was recommended for all infants, and other studies suggested it reduced by 20 percent. But questions lingered about whether the pneumonia reduction would last, or if other, less common pneumococcal types might actually increase to fill the void left by those types covered by the vaccine.

"Sometimes when you eliminate one serotype, others become more apparent. Following the introduction of PCV7, there was an increase in pneumococcal diseases caused by a serotype called 19A, not included in that vaccine. That's why it is really important to keep studying this and seeing what happens," Griffin said.

19A is one of the pneumococcal serotypes included in the newer version of the vaccine introduced in 2010. The vaccine now protects against 13 types of pneumococcus. Researchers say they are optimistic the newer vaccine may continue to provide both direct and herd effects in the future.

"PCV13 may cause another large reduction in pneumonia hospitalizations; perhaps another 10 percent, we hope. It is important for people to know that adults are benefiting from our childhood vaccine program. These are adults who won't be hospitalized, won't be getting antibiotics, or complications of hospitalizations, and won't be dying, since the risk of death is 5 percent to 12 percent when are hospitalized with pneumonia. Vaccination of infants with pneumococcal conjugate vaccines results in a tremendous public health benefit," Griffin said.

Explore further: European regulators expand Pfizer vaccine approval

Related Stories

European regulators expand Pfizer vaccine approval

July 10, 2013
European regulators have become the first to approve Pfizer Inc.'s Prevenar 13 vaccine for patients at all stages of life by including adults between the ages of 18 and 49.

Vaccinating adults with new pneumonia vaccine more cost-effective: researcher

February 24, 2012
(Medical Xpress) -- A new study suggests vaccinating adults against one of the most common causes of pneumonia with a new vaccine, which has virtually eliminated this infection in children, is more cost effective than using ...

Study to test pneumococcal vaccine in older adults

October 15, 2012
Researchers plan to see if a higher dose of a pneumococcal vaccine will create a stronger immune response in older adults who received an earlier generation vaccine against pneumonia and other pneumococcal diseases.

Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine

May 22, 2013
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...

Pneumococcal rates plunge after widespread vaccination of infants

May 27, 2013
The number of young children contracting the most common strains of potentially fatal pneumococcal disease has plummeted 97% since the universal vaccination against this bacterial disease began in 2005, with unvaccinated ...

An ally against childhood pneumonia

June 18, 2013
(Medical Xpress)—Since 2000, children born in the United States benefit from the research of Keith Klugman, who helped develop the pneumonia vaccine that is now part of their immunization regimen. As a result, invasive ...

Recommended for you

Fresh approach to tuberculosis vaccine offers better protection

January 17, 2018
A unique platform that resulted in a promising HIV vaccine has also led to a new, highly effective vaccine against tuberculosis that is moving toward testing in humans.

Study reveals how MRSA infection compromises lymphatic function

January 17, 2018
Infections of the skin or other soft tissues with the hard-to-treat MRSA (methicillin-resistant Staphylococcus aureus) bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. ...

Newly-discovered TB blood signal provides early warning for at-risk patients

January 17, 2018
Tuberculosis can be detected in people with HIV infection via a unique blood signal before symptoms appear, according to a new study by researchers from the Crick, Imperial College London and the University of Cape Town.

New study validates clotting risk factors in chronic kidney disease

January 17, 2018
In late 2017, researchers from Boston University School of Medicine (BUSM) discovered and published (Science Translational Medicine, (9) 417, Nov 2017) a potential treatment target to prevent chronic kidney disease (CKD) ...

New study offers insights on genetic indicators of COPD risk

January 16, 2018
Researchers have discovered that genetic variations in the anatomy of the lungs could serve as indicators to help identify people who have low, but stable, lung function early in life, and those who are particularly at risk ...

Previous influenza virus exposures enhance susceptibility in another influenza pandemic

January 16, 2018
While past exposure to influenza A viruses often builds immunity to similar, and sometimes different, strains of the virus, Canadian researchers are calling for more attention to exceptions to that rule.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.